OncLive TV

Dr. Martin Reck on Docetaxel/Ramucirumab in NSCLC

July 14th 2016

Dr. Blum on Takeaways from ABC Trials for Breast Cancer

July 14th 2016

Joanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the key takeaways from the phase III ABC (anthracyclines in early breast cancer) trials, which compared docetaxel plus cyclophosphamide versus anthracycline/taxane-based chemotherapy regimens in patients with high-risk, HER2-negative breast cancer.

Dr. Heinemann on Surrogate Markers Beyond PFS in Patients With CRC

July 14th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses surrogate markers aside from progression-free survival (PFS) in studying patients with colorectal cancer (CRC).

Dr. Haraf on Induction Chemotherapy With Radiation For Advanced Head and Neck Cancer

July 14th 2016

Dr. Sharma on Results of SIRFLOX Study for CRC

July 14th 2016

Navesh K. Sharma, DO, PhD, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study, which examined the addition of Yttrium-90 (Y-90) resin microspheres (SIR-Spheres) to standard frontline FOLFOX-based chemotherapy with or without bevacizumab for patients with liver metastatic colorectal cancer (CRC).

Dr. Rosenberg on Future Use of Atezolizumab in Bladder Cancer

July 13th 2016

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses ongoing research of and next steps with atezolizumab (Tecentriq) for the treatment of patients with metastatic urothelial carcinoma.

Dr. Nicholas Robert on MA.17R Trial for Patients With Early-Stage Breast Cancer

July 13th 2016

Nicholas J. Robert, MD, medical oncology, hematology, Virginia Cancer Specialists, US Oncology, discusses the MA.17R trial, which explored an extension of adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.

Dr. Jennifer Brown on the Role of FCR in CLL

July 13th 2016

Dr. Kanwal Raghav on the Biology of HER2 Gene Amplification in mCRC

July 13th 2016

Dr. McDermott on Long-Term Benefit With Nivolumab in RCC

July 12th 2016

David F. McDermott, MD, associate professor of Medicine, Harvard Medical School, staff physician, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses long-term follow-up results of treatment with nivolumab (Opdivo) for patients with renal cell carcinoma (RCC).

Dr. Hamilton on ONT-380/T-DM1 in HER2+ Breast Cancer

July 12th 2016

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase Ib study examining ONT-380 in combination with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer, and what potential the combination has in the neoadjuvant setting.

Dr. George D. Demetri on the Impact of Sarcoma Subtyping on Other Cancers

July 12th 2016

Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Multiple Myeloma

July 12th 2016

Dr. Taplin on ARMOR 3-SV Trial for Patients with mCRPC

July 11th 2016

Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Overman on Implications of Tumor Location Data for Patients With mCRC

July 11th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the results of the phase III FIRE-3 and 80405 studies will impact treatment of patients with metastatic colorectal cancer.

Dr. Loppenberg on Benefits of Local Treatment for Metastatic Prostate Cancer

July 11th 2016

Dr. Howard Burris on Patient-Reported Outcomes of MARIANNE

July 9th 2016

Dr. Jonathan Trent on Engineered T- cell Therapy in Sarcoma

July 9th 2016

Dr. Saad on Patients With mCRPC Eligible for 6-Doses of Radium-223

July 8th 2016

Fred Saad, MD, professor and chairman of Urology, director of GU Oncology, the University of Montreal Hospital Centers, discusses results of an analysis that examined which patients with metastatic castration-resistant prostate cancer are able to receive the recommended 6-doses of radium-223 dichloride (Xofigo).

Dr. Byrd on Alacabrutinib's Mechanism of Action in CLL

July 8th 2016

John Byrd, MD, director of the Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center, discusses the mechanism of acalabrutinib, a next-generation BTK inhibitor as a potential treatment for patients with chronic lymphocytic leukemia.